By reviewing the data and tweets, can we predict if the closing price of $amgn will go upwards or downwards at 2017-02-27? Please indicate either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-02-10,-0.1,0.3,-0.5,0.3,0.3,-0.3,-2.6,-4.6,-5.3,-5.5,-6.4
2017-02-13,0.0,0.4,-0.6,-0.1,0.6,-0.6,-2.3,-4.4,-5.5,-5.8,-6.5
2017-02-14,-0.6,0.0,-1.5,0.2,0.2,-0.5,-1.8,-4.0,-5.3,-5.7,-6.2
2017-02-15,-2.6,0.1,-2.8,2.2,2.2,-2.1,-3.2,-5.3,-6.8,-7.5,-7.8
2017-02-16,-0.3,0.0,-1.1,0.2,0.2,-1.7,-2.6,-4.7,-6.4,-7.2,-7.6
2017-02-17,-1.1,0.0,-2.5,0.7,0.7,-1.6,-2.8,-4.7,-6.5,-7.4,-7.8
2017-02-21,-0.2,0.2,-0.7,-0.1,-0.1,-0.8,-2.3,-3.9,-5.8,-6.9,-7.4
2017-02-22,-0.2,1.2,-0.4,-0.3,-0.3,-0.0,-1.6,-2.9,-4.9,-6.2,-6.9
2017-02-23,-0.7,0.0,-1.2,0.8,0.8,-0.6,-2.0,-3.1,-5.1,-6.5,-7.3
2017-02-24,-0.7,0.1,-1.2,0.3,0.3,-0.6,-1.8,-2.8,-4.7,-6.3,-7.2

2017-02-10: $amgn max pain is 155.00 for maturity 02/17/2017. prev close = 167.47.   |biotech etfs powered by q4 earnings $ibb $bbh $fbt also $amgn $vrtx $ilmn $celg $gild $biib |rt AT_USER aca, virtual reality, 
2017-02-11: rt AT_USER isi slide.  case to be made big cap biotech cheap here &amp; maybe even cheaper then big pharma ? $gild $celg $amgn $biib $regn¡­|$amgn high open interest range is 140.00 to 160.00 for opti
2017-02-12: rt AT_USER pharma m&amp;a in 2017: the most likely deal hunters  $amgn $gild $mrk $pfe|rt AT_USER pharma stocks getting clobbered.. great buying opportunity for the long term! $bmy $agn $abbv $pfe $mr
2017-02-13: rt AT_USER an examination of relative strength among biotech may provide a few trades. $regn $alxn $amgn $ilmn software available at AT_USER|rt AT_USER an examination of relative strength among biotec
2017-02-14: remarkable how well these names have performed since last month's tweet. $abt $amgn $bsx $cnc $esrx $ilmn $lly $rmd¡­ |amgen $amgn revenues boost 6% in 4q, driven by drug sales &amp; price hikes. yet,
2017-02-15: interview with connor bruggeman schooltrader extraordinaire!:  $nflx $himx $ino $amgn $googl|thursday: $shld, $juno, $amgn, $celg, $adi, $prgo, $gild, $cf, $fosl, $trip, $mnk, $bmy|all about the heart
2017-02-16: $amgn oi for maturity 02/17/2017. 155.00 highest put. 167.50 highest call.  |don't count on valeant's new drug to save the day $amgn $azn $vrx |AT_USER agree $amgn interesting, but  terms/clinical pro
2017-02-17: genentech fighting to delay looming market entry of amgen's avastin biosimilar  $rhhby $amgn|rt AT_USER biotech giants square off in 'biosimilar' fight for top-selling cancer drug  via AT_USER|genente
2017-02-18: $spx spdr health care sector etf components. $bmy $gld $unh $abbv $biib $jnj $mdt $xlv $lly $pfe $celg $mrk $tmo¡­ |rt AT_USER lobbyist for $amgn and $pfe among mar-a-lago members |$amgn oi for maturi
2017-02-19: $amgn max pain = 167.50. maturity = 02/24/2017. previous close = 173.29.   |$amgn:us mission wealth management llc purchases 30 shares of amgen inc. (amgn) #amgen inc   #nasdaq|$amgn amgen 173.29 had 
2017-02-20: $aapl $amat $amgn $amtd $amzn $atvi trade long and short positions from the #nasdaq, up to 1500% since 2010.¡­ |rt AT_USER #genentech files complaint over $amgn amgen¡¯s development of avastin biosimi
2017-02-21: AT_USER AT_USER i could see $amgn. maybe $gsk. maybe $celg tries merger of equals?|after that q4 cc i think $bmy will have a hard time fighting of AT_USER think $pfe and $nvs maybe $amgn $gild pot sui
2017-02-22: harvard pilgrim notches new agreements with $amgn and $lly |$amgn has a shot here on the monthly, too. |rt AT_USER #biotech...timeless advice......5 golden rules for better biotech investing  $abbv $a
2017-02-23: $amgn amgen wins marketing authorization for #repatha (evolocumab) single-dose delivery option  via AT_USER|rt AT_USER icymi wednesday: amgen strikes enbrel 'outcomes' contract with harvard pilgrim  $
2017-02-24: rt AT_USER bought near ipo $24.80 still own. long term wealth build rule; when get initial capital back take out invest diverse port re¡­|what should you look for in exelixis, inc. $exel 4q earnings? 
2017-02-25: $amgn max pain = 167.50. maturity = 03/03/2017. previous close = 174.56.   |3 breakout stocks for march 2017 $dal $amgn $rng |harvard pilgrim inks deal with $lly and $amgn |$amgn rose in the past few 
Answer:
By reviewing the data and tweets, can we predict if the closing price of $amgn will go upwards or downwards at 2017-02-27? Please indicate either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-02-10,-0.1,0.3,-0.5,0.3,0.3,-0.3,-2.6,-4.6,-5.3,-5.5,-6.4
2017-02-13,0.0,0.4,-0.6,-0.1,0.6,-0.6,-2.3,-4.4,-5.5,-5.8,-6.5
2017-02-14,-0.6,0.0,-1.5,0.2,0.2,-0.5,-1.8,-4.0,-5.3,-5.7,-6.2
2017-02-15,-2.6,0.1,-2.8,2.2,2.2,-2.1,-3.2,-5.3,-6.8,-7.5,-7.8
2017-02-16,-0.3,0.0,-1.1,0.2,0.2,-1.7,-2.6,-4.7,-6.4,-7.2,-7.6
2017-02-17,-1.1,0.0,-2.5,0.7,0.7,-1.6,-2.8,-4.7,-6.5,-7.4,-7.8
2017-02-21,-0.2,0.2,-0.7,-0.1,-0.1,-0.8,-2.3,-3.9,-5.8,-6.9,-7.4
2017-02-22,-0.2,1.2,-0.4,-0.3,-0.3,-0.0,-1.6,-2.9,-4.9,-6.2,-6.9
2017-02-23,-0.7,0.0,-1.2,0.8,0.8,-0.6,-2.0,-3.1,-5.1,-6.5,-7.3
2017-02-24,-0.7,0.1,-1.2,0.3,0.3,-0.6,-1.8,-2.8,-4.7,-6.3,-7.2

2017-02-10: $amgn max pain is 155.00 for maturity 02/17/2017. prev close = 167.47.   |biotech etfs powered by q4 earnings $ibb $bbh $fbt also $amgn $vrtx $ilmn $celg $gild $biib |rt AT_USER aca, virtual reality, 
2017-02-11: rt AT_USER isi slide.  case to be made big cap biotech cheap here &amp; maybe even cheaper then big pharma ? $gild $celg $amgn $biib $regn¡­|$amgn high open interest range is 140.00 to 160.00 for opti
2017-02-12: rt AT_USER pharma m&amp;a in 2017: the most likely deal hunters  $amgn $gild $mrk $pfe|rt AT_USER pharma stocks getting clobbered.. great buying opportunity for the long term! $bmy $agn $abbv $pfe $mr
2017-02-13: rt AT_USER an examination of relative strength among biotech may provide a few trades. $regn $alxn $amgn $ilmn software available at AT_USER|rt AT_USER an examination of relative strength among biotec
2017-02-14: remarkable how well these names have performed since last month's tweet. $abt $amgn $bsx $cnc $esrx $ilmn $lly $rmd¡­ |amgen $amgn revenues boost 6% in 4q, driven by drug sales &amp; price hikes. yet,
2017-02-15: interview with connor bruggeman schooltrader extraordinaire!:  $nflx $himx $ino $amgn $googl|thursday: $shld, $juno, $amgn, $celg, $adi, $prgo, $gild, $cf, $fosl, $trip, $mnk, $bmy|all about the heart
2017-02-16: $amgn oi for maturity 02/17/2017. 155.00 highest put. 167.50 highest call.  |don't count on valeant's new drug to save the day $amgn $azn $vrx |AT_USER agree $amgn interesting, but  terms/clinical pro
2017-02-17: genentech fighting to delay looming market entry of amgen's avastin biosimilar  $rhhby $amgn|rt AT_USER biotech giants square off in 'biosimilar' fight for top-selling cancer drug  via AT_USER|genente
2017-02-18: $spx spdr health care sector etf components. $bmy $gld $unh $abbv $biib $jnj $mdt $xlv $lly $pfe $celg $mrk $tmo¡­ |rt AT_USER lobbyist for $amgn and $pfe among mar-a-lago members |$amgn oi for maturi
2017-02-19: $amgn max pain = 167.50. maturity = 02/24/2017. previous close = 173.29.   |$amgn:us mission wealth management llc purchases 30 shares of amgen inc. (amgn) #amgen inc   #nasdaq|$amgn amgen 173.29 had 
2017-02-20: $aapl $amat $amgn $amtd $amzn $atvi trade long and short positions from the #nasdaq, up to 1500% since 2010.¡­ |rt AT_USER #genentech files complaint over $amgn amgen¡¯s development of avastin biosimi
2017-02-21: AT_USER AT_USER i could see $amgn. maybe $gsk. maybe $celg tries merger of equals?|after that q4 cc i think $bmy will have a hard time fighting of AT_USER think $pfe and $nvs maybe $amgn $gild pot sui
2017-02-22: harvard pilgrim notches new agreements with $amgn and $lly |$amgn has a shot here on the monthly, too. |rt AT_USER #biotech...timeless advice......5 golden rules for better biotech investing  $abbv $a
2017-02-23: $amgn amgen wins marketing authorization for #repatha (evolocumab) single-dose delivery option  via AT_USER|rt AT_USER icymi wednesday: amgen strikes enbrel 'outcomes' contract with harvard pilgrim  $
2017-02-24: rt AT_USER bought near ipo $24.80 still own. long term wealth build rule; when get initial capital back take out invest diverse port re¡­|what should you look for in exelixis, inc. $exel 4q earnings? 
2017-02-25: $amgn max pain = 167.50. maturity = 03/03/2017. previous close = 174.56.   |3 breakout stocks for march 2017 $dal $amgn $rng |harvard pilgrim inks deal with $lly and $amgn |$amgn rose in the past few 
Answer:+Rise